Age, Creatinine, Ejection Fraction Predict Post-MI Survival

This article originally appeared here.
Share this content:
Age, Creatinine, Ejection Fraction Predict Post-MI Survival
Age, Creatinine, Ejection Fraction Predict Post-MI Survival

MONDAY, April 20, 2015 (HealthDay News) -- A simple age, creatinine, and ejection fraction (ACEF) score can predict one-year mortality risk in myocardial infarction 30-day survivors who underwent percutaneous coronary intervention, according to a study published in the May 1 issue of The American Journal of Cardiology.

Jang Hoon Lee, M.D., from Kyungpook National University Hospital in Daegu, South Korea, and colleagues examined whether the ACEF score could predict one-year mortality for 12,000 post-myocardial infarction 30-day survivors who underwent percutaneous coronary intervention. Twelve risk factors were selected and ranked based on their area under the curve (AUC) value.

The researchers found that the best AUC value was indicated by age, ejection fraction, and serum creatinine levels. Nonsurvivors had a significantly higher ACEF score (1.95 ± 0.82 versus 1.28 ± 0.5); the ACEF score independently predicted one-year mortality (adjusted hazard ratio, 2.26). A prediction model including 12 risk factors had the best accuracy (AUC, 0.8), but this was not significantly different from the ACEF score (AUC, 0.79). For the ACEFLOW, ACEFMID, and ACEFHIGH groups, the adjusted hazard ratios for one-year mortality were 1 (reference), 3.11, and 10.38, respectively.

"The ACEF score may be a novel valid model to stratify the one-year mortality risk in 30-day survivors who underwent percutaneous coronary intervention after myocardial infarction," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »